[18F]FETO for adrenocortical PET imaging: a pilot study in healthy volunteers

Wadsak, Wolfgang; Mitterhauser, Markus; Rendl, Gundula; Schuetz, Matthias; Mien, Leonhard Key; Ettlinger, Dagmar E.; Dudczak, Robert; Kletter, Kurt; Karanikas, Georgios

doi:10.1007/s00259-005-0062-6

Cited by 31 publications

(12 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the binding of MTO to the 11β‐hydroxylase activity, the differential diagnosis of adrenocortical carcinomas versus other adrenal tumours such as phaeochromocytomas is possible using 11 C‐MTO also in the presence of extended necrosis (Hennings et al., 2006). 18 F‐FETO has also shown promise in imaging for adrenocortical imaging (Wadsak et al., 2006).…”

Section: Pet and Pet/ctmentioning

confidence: 99%

Imaging and cancer: A review

2008

View full text Add to dashboard Cite

Multiple biomedical imaging techniques are used in all phases of cancer management. Imaging forms an essential part of cancer clinical protocols and is able to furnish morphological, structural, metabolic and functional information. Integration with other diagnostic tools such as in vitro tissue and fluids analysis assists in clinical decision-making. Hybrid imaging techniques are able to supply complementary information for improved staging and therapy planning. Image guided and targeted minimally invasive therapy has the promise to improve outcome and reduce collateral effects. Early detection of cancer through screening based on imaging is probably the major contributor to a reduction in mortality for certain cancers. Targeted imaging of receptors, gene therapy expression and cancer stem cells are research activities that will translate into clinical use in the next decade. Technological developments will increase imaging speed to match that of physiological processes. Targeted imaging and therapeutic agents will be developed in tandem through close collaboration between academia and biotechnology, information technology and pharmaceutical industries.

show abstract

Section: Pet and Pet/ctmentioning

confidence: 99%

Imaging and cancer: A review

2008

View full text Add to dashboard Cite

show abstract

“…Several other 18 F-labelled metomidate analogues have also been proposed as adrenocortical imaging agents, but none have subsequently translated to clinical studies [55]. The only human study of 18 F-FETO, conducted in ten healthy volunteers, showed very high adrenocortical uptake and physiological distribution in the liver, renal calyces, gallbladder, stomach wall, and pancreas, with only faint uptake in the kidney and bowel [56]. Further clinical studies have, however, been lacking.…”

Section: 123/124/131i-iodometomidate Imaging In Adrenal Diseasementioning

confidence: 99%

Targeted Molecular Imaging in Adrenal Disease—An Emerging Role for Metomidate PET-CT

et al. 2016

View full text Add to dashboard Cite

Adrenal lesions present a significant diagnostic burden for both radiologists and endocrinologists, especially with the increasing number of adrenal ‘incidentalomas’ detected on modern computed tomography (CT) or magnetic resonance imaging (MRI). A key objective is the reliable distinction of benign disease from either primary adrenal malignancy (e.g., adrenocortical carcinoma or malignant forms of pheochromocytoma/paraganglioma (PPGL)) or metastases (e.g., bronchial, renal). Benign lesions may still be associated with adverse sequelae through autonomous hormone hypersecretion (e.g., primary aldosteronism, Cushing’s syndrome, phaeochromocytoma). Here, identifying a causative lesion, or lateralising the disease to a single adrenal gland, is key to effective management, as unilateral adrenalectomy may offer the potential for curing conditions that are typically associated with significant excess morbidity and mortality. This review considers the evolving role of positron emission tomography (PET) imaging in addressing the limitations of traditional cross-sectional imaging and adjunctive techniques, such as venous sampling, in the management of adrenal disorders. We review the development of targeted molecular imaging to the adrenocortical enzymes CYP11B1 and CYP11B2 with different radiolabeled metomidate compounds. Particular consideration is given to iodo-metomidate PET tracers for the diagnosis and management of adrenocortical carcinoma, and the increasingly recognized utility of 11C-metomidate PET-CT in primary aldosteronism.

show abstract

“…18 F-FE-TO/PET was shown to be significantly accumulated in the human adrenals of healthy volunteers [15]. Median SUVs in the adrenals were 6 times as high as that in the liver as a reference tissue [25]. Although these results indicated 11 C-ETO/PET and 18 F-FETO/PET are potentially useful for functional imaging of adrenocortical tumor, no additional study has been published in patients with adrenocortical diseases including PA.…”

Section: Etomidatementioning

confidence: 99%

The Latest Developments of Functional Molecular Imaging in the Diagnosis of Primary Aldosteronism

et al. 2017

View full text Add to dashboard Cite

Differentiation of unilateral from bilateral aldosterone hypersecretion is the essential step in the clinical practice of primary aldosteronism (PA). Although adrenal venous sampling (AVS) has been established as the most standard test recommended by the guideline, its invasive and technically difficult nature has facilitated the approach to develop non-invasive functioning imaging as an alternative test. Compared to the conventional adrenocortical scintigraphy with cholesterol derivatives as tracer, the first-generation imaging, both of C-MTO/PET andI-IMTO/SPECT/CT, the second-generation imaging, bind with high specificity and affinity to CYP11B enzymes and have advantages in shortening the time for obtaining specific images, reducing the radiation exposure to the patient, and resolution of the images. Because of very short half-life of C-MTO,I-IMTO has a potential for a wider application than C-MTO. Sensitivity of identifying an adenoma smaller than 1 cm in diameter is still a common limitation of these new functional imaging methods. The new functional imaging could be supplementary to AVS in lateralization of PA when the results of AVS are not conclusive. To be a substitute for AVS, however, it should fulfill various conditions including high selectivity and binding affinity to CYP11B2, high sensitivity in detecting small adenoma, high resolution image, reduction of radiation exposure, and general versatility. Considering the potential number of patients, cost-effectiveness of the subtype testing in the clinical practice of PA could be one of the issues of the medical expenses. Thus, development of a new non-invasive functional imaging will have a significant impact on the clinical practice of PA and hypertension.

show abstract

[18F]FETO for adrenocortical PET imaging: a pilot study in healthy volunteers

Abstract: [(18)F]FETO is a valuable tracer for adrenocortical PET imaging, combining the longer half-life of( 18)F with a high 11beta-hydroxylase selectivity. In accordance with our findings in rats, FETO PET revealed very high accumulation in the adrenal glands in healthy volunteers.

Cited by 31 publications

References 5 publications

Imaging and cancer: A review

Imaging and cancer: A review

Targeted Molecular Imaging in Adrenal Disease—An Emerging Role for Metomidate PET-CT

The Latest Developments of Functional Molecular Imaging in the Diagnosis of Primary Aldosteronism

Contact Info

Product

Resources

About